user

COMBINED ENZYME-REPLACEMENT AND SUBSTRATE-REDUCTION THERAPIES IN GAUCHER DISEASE TYPE II/III

被引：0
|
作者：
Gautschi, M. [1 ]
Nava, E. [2 ]
Simonetti, Goeggel B. [2 ]
Nuoffer, J. M. [3 ]
机构：
[1] Univ Child Hosp, Interdiscipl Metab Unit, Bern, Switzerland
[2] Univ Child Hosp, Neuropediat Unit, Bern, Switzerland
[3] Univ Hosp Bern, Inst Clin Chem, CH-3010 Bern, Switzerland
来源：
JOURNAL OF INHERITED METABOLIC DISEASE | 2011年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：S200 / S200
页数：1
相关论文
共 50 条
  • [21] Attitudes of Individuals with Gaucher Disease toward Substrate Reduction Therapies
    Wagner, Victoria F.
    Northrup, Hope
    Hashmi, S. Shahrukh
    Nguyen, Joanne M.
    Koenig, Mary Kay
    Davis, Jessica M.
    JOURNAL OF GENETIC COUNSELING, 2018, 27 (01) : 169 - 176
  • [22] Enzyme replacement therapy in type 2 Gaucher disease
    Tournay, A
    Parker, C
    Schiffman, R
    Brady, R
    Barton, N
    NEUROLOGY, 1996, 46 (02) : 1106 - 1106
  • [23] The need for standardization of immunogenicity assays for Gaucher disease enzyme replacement therapies
    Keutzer, Joan
    Richards, Susan
    Yeh, Michael
    Yee, John
    MOLECULAR GENETICS AND METABOLISM, 2009, 96 (02) : S28 - S28
  • [24] THE NEED FOR STANDARDIZATION OF IMMUNOGENICITY ASSAYS FOR GAUCHER DISEASE ENZYME REPLACEMENT THERAPIES
    Keutzer, J.
    Richards, S.
    Graham, S.
    Yee, J.
    CLINICAL THERAPEUTICS, 2009, 31 : S207 - S207
  • [25] Management of lysosomal glycosphingolipid levels in animal models of Gaucher and Fabry disease with enzyme and substrate reduction therapies
    Marshall, John
    Ashe, Karen
    Chuang, WeiLien
    Copeland, Diane
    Scheule, Ronald
    Cheng, Seng
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (02) : S26 - S26
  • [26] The overall response to enzyme replacement therapy (ERT) in type III Gaucher with aggressive systemic disease
    Altarescu, G
    Kaneski, CR
    Kreps, C
    Barton, NW
    Schiffmann, R
    BLOOD, 1998, 92 (10) : 19A - 19A
  • [27] ENZYME REPLACEMENT THERAPY IN GAUCHER DISEASE TYPE-1
    AGGIO, MC
    FERNANDEZ, V
    MARCILESE, M
    MEDICINA-BUENOS AIRES, 1994, 54 (02) : 140 - 144
  • [28] ENZYME REPLACEMENT THERAPY IN TYPE-I GAUCHER DISEASE
    KAY, AC
    BEUTLER, E
    CLINICAL RESEARCH, 1991, 39 (02): : A326 - A326
  • [29] Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158"
    Hughes, Derralynn. A. A.
    Deegan, Patrick
    Giraldo, Pilar
    Goker-Alpan, Ozlem
    Lau, Heather
    Lukina, Elena
    Revel-Vilk, Shoshana
    Scarpa, Maurizio
    Botha, Jaco
    Gadir, Noga
    Zimran, Ari
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (12)
  • [30] Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
    Limgala, Renuka P.
    Goker-Alpan, Ozlem
    BIOMOLECULES, 2020, 10 (04)
12345